Benzonatate modified release solid tablets and capsules
A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
1. A modified release solid oral composition comprising:
a matrix comprising (a) an adsorbate powder comprising benzonatate adsorbed to a silicon dioxide, and (b) at least one hydrophilic matrix forming material, and
a reverse enteric coating, wherein the composition provides benzonatate having a pharmacokinetic profile characterized by one or more of: an arithmetic mean Cmax of about 52 ng/mL, an arithmetic mean Cmax of about 60 ng/mL, a geometric mean AUCinf of about 137 ng·h/mL or an arithmetic mean AUCinf of about 160 ng·h/mL.
2. The modified release solid oral composition according to claim 1 , wherein the composition comprises mini-tabs loaded into a capsule.
3. The modified release solid oral composition according to claim 1 , wherein the weight ratio of benzonatate to the amorphous adsorbent is in the range of about 5:1 to about 1:10.
4. The modified release solid oral composition according to claim 1 , which comprises about 5% w/w to about 35% w/w, or about 5% w/w to about 30% w/w of the at least one hydrophilic polymer, based on the weight of the homogenous solid dispersion.
5. The modified release solid oral composition according to claim 4 , wherein the matrix-forming substance comprises a low viscosity, hydrophilic polymer which is a hydroxypropyl methylcellulose having a viscosity of about 4000 mPa-s to about 100,000 mPa-s, or a blend of polymers containing said hydroxypropyl methycellulose.
6. The modified release solid oral composition according to claim 1 , wherein said reverse enteric coating comprises (a) a pH-dependent methyl methacrylate and diethylaminoethyl methacrylate copolymer or (b) a pH-dependent cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate.
7. The modified release solid oral composition according to claim 6 , wherein said reverse enteric coating comprises a pH-dependent cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate.
8. The modified release solid oral composition according to claim 6 , wherein said reverse enteric coating comprises about 5% to about 40% weight of said composition.
9. The modified release solid oral composition according to claim 6 which is a compressed tablet.
10. The modified release solid oral composition according to claim 9 , wherein the tablet further comprises at least one excipient selected from one or more of bulking agents, binders, and lubricants.
11. The modified release solid oral composition according to claim 1 , wherein said tablet further comprises at least one or more additional pharmaceutically active components.
12. The modified release solid oral composition according to claim 1 , wherein said at least one or more additional active components is selected from an anti-pyretic, an analgesic, an anti-histamine, an expectorant and a decongestant.
13. The modified release solid oral composition according to claim 12 , wherein said at least one or more additional active components are independently in immediate release form, in modified release form, or both.
14. The modified release solid oral composition according claim 1 , wherein said at least one or more additional active components-is the expectorant guaifenesin.
15. The modified release solid oral composition according to claim 14 , wherein at least one of the one or more additional active components is in the matrix.
16. The modified release solid oral composition according to claim 1 , wherein the adsorbate powder of (a)(i) comprises particles having an average size of about 50 μm to about 200 μm.
17. The modified release solid oral composition according to claim 1 , wherein the adsorbate powder of (a)(i) comprises at least about 55% w/w to about 60% w/w benzonatate.
18. The modified release benzonatate solid composition according to claim 1 , wherein said reverse enteric coat comprises a butylated methacrylate copolymer.
19. The modified release benzonatate solid composition according to claim 1 , wherein said solid dispersion further comprises one or more of microcrystalline cellulose, copovidone, hypromellose and magnesium stearate.
20. A modified release solid oral composition comprising: (a) an adsorbate powder comprising benzonatate adsorbed to one or more of a silicon dioxide, (b) a hydrophobic or hydrophilic matrix forming material, and a reverse enteric coating, the composition provides benzonatate having a pharmacokinetic profile characterized by one or more of: a geometric mean maximum plasma concentration which has an area under the curve (AUC)inf of about 150 ng-h/mL and/or a Cmax of about 30 ng/mL.